Skip to main content
. 2008 Apr 28;9(2):69–82. doi: 10.1120/jacmp.v9i2.2794

Table 3.

Patients sorted in descending order by absolute value of the difference between total lung V20 obtained by using lung, heart, cord (LHC) for deformation and total lung V20 obtained by using lung, heart, cord, external contour (LHCE) for lung deformation

Patient Total lung V20 difference (%) Tumor site Disease stage Prescription dose and fractionation scheme Hypofx?
10 2.59 Squamous mid‐esophagus T3N1M0 50.4 Gy, 28 fractions No
5 1.82 NSCLC LUL T1N2M0 63 Gy, 35 fractions No
9 1.47 NSCLC RUL T1N2M1 60 Gy, 30 fractions No
3 1.19 Adenocarcinoma, distal esophagus T3N1M0 50.4 Gy, 28 fractions No
8 1.14 Adenocarcinoma RUL T1N1M0 recurrent 63 Gy, 30 fractions No
2 0.69 NSCLC RLL (post surgery) T2M2N0 50.4 Gy, 28 fractions No
7 0.52 Squamous‐cell carcinoma RLL T2N2M0 63 Gy, 35 fractions No
6
0.29
NSCLC LUL T1N0M0 50 Gy, 4 fractions Yes
1 0.08 NSCLC left lung T3N2M1 60 Gy, 20 fractions No
4
0.03
NSCLC RUL T1N0M0 70 Gy, 35 fractions No

V20=fractionalvolumeofanatomicstructurereceivingatleast20Gy; Hypofx=hypofractionated; NSCLC=nonsmallcelllungcancer; LUL=leftupperlobe; RUL=rightupperlobe; RLL=rightlowerlobe.